198 related articles for article (PubMed ID: 24332355)
21. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
22. Anti-epidermal growth factor receptor skin toxicity: a matter of topical hydration.
Ferrari D; Codecà C; Bocci B; Crepaldi F; Violati M; Viale G; Careri C; Caldiera S; Bordin V; Luciani A; Zonato S; Cassinelli G; Foa P
Anticancer Drugs; 2016 Feb; 27(2):144-6. PubMed ID: 26469836
[TBL] [Abstract][Full Text] [Related]
23. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
25. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients.
Roayaei M; Rezaei M; Najafizade N
Adv Biomed Res; 2023; 12():260. PubMed ID: 38192897
[TBL] [Abstract][Full Text] [Related]
27. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
Giuliani J; Marzola M
J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
[TBL] [Abstract][Full Text] [Related]
28. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
Saif MW; Longo WL; Israel G
Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
30. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
31. A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
Hashimoto H; Iwasa S; Yanai T; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Namikawa K; Tsutsumida A; Yamazaki N; Yamamoto H
Jpn J Clin Oncol; 2013 Jan; 43(1):92-4. PubMed ID: 23136238
[TBL] [Abstract][Full Text] [Related]
32. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
[TBL] [Abstract][Full Text] [Related]
33. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
34. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash.
Eriksen JG; Kaalund I; Clemmensen O; Overgaard J; Pfeiffer P
Support Care Cancer; 2017 Jul; 25(7):2179-2185. PubMed ID: 28197850
[TBL] [Abstract][Full Text] [Related]
35. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Giuliani J; Marzola M
Arch Dermatol Res; 2013 Sep; 305(7):653-8. PubMed ID: 23536039
[TBL] [Abstract][Full Text] [Related]
36. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
37. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
38. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer.
Ito C; Fujii H; Ogura M; Sato H; Kusano E
J Oncol Pharm Pract; 2013 Sep; 19(3):265-8. PubMed ID: 23047237
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab-induced cutaneous toxicity.
Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]